Osteosarcoma in Children
12
3
5
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
2 terminated out of 12 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Tissue Expression of Krüppel-Like Factors 4 and 7 in Bone Tumors
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma
Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
Long-term Evaluation of the Quality of Life of Former Patients Treated With Orthopedic Surgery, With or Without Radiotherapy
3D Printed Personalized Extendable Prosthesis
Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity
Integrated Clinical-radiological Analysis of Hypoxia Markers in Pediatric Osteosarcomas